[Proton pump inhibitors and clopidogrel: an association to avoid?]

Area of Science:

• Cardiology
• Pharmacology
• Gastroenterology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces cardiovascular events after acute coronary syndrome or stent implantation.
• Gastrointestinal (GI) bleeding risk associated with DAPT often leads to co-administration of proton pump inhibitors (PPIs).
• Ex vivo studies suggest PPIs may decrease clopidogrel's antiplatelet effects, raising safety concerns for this combination.

Purpose of the Study:

• To investigate the clinical effects of the interaction between proton pump inhibitors (PPIs) and clopidogrel.
• To resolve conflicting results from previous clinical trials on PPI-clopidogrel interaction.
• To determine the safety and efficacy of co-administering PPIs with clopidogrel.

Main Methods:

• Review of existing clinical trials and their limitations.
• Discussion of the premature termination of the COGENT trial, a planned prospective, double-blind, randomized, placebo-controlled study.
• Analysis of PPIs' affinity for CYP2C19 and its implications.

Main Results:

• Clinical trials investigating PPI-clopidogrel interaction have yielded conflicting and criticized results.
• A definitive prospective, double-blind, randomized, placebo-controlled study with adequate sample size and follow-up has not yet been completed.
• The clinical effects of PPI-clopidogrel interaction remain unresolved and cannot be excluded.

Conclusions:

• The clinical significance of PPI-clopidogrel interaction remains uncertain due to conflicting evidence and lack of robust studies.
• Combination therapy should be reserved for high-risk bleeding patients.
• Clinicians should avoid PPIs with high CYP2C19 affinity, such as omeprazole and esomeprazole, in this patient population.